Sat, Dec 27, 2014, 2:23 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

get648 21 posts  |  Last Activity: Dec 11, 2014 3:04 PM Member since: Dec 14, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • get648 get648 Dec 11, 2014 3:04 PM Flag

    Exactly - they want you to sell your shares.
    The same happened with AVNR near 11,80 an 13,00 months ago.

    Sentiment: Strong Buy

  • baker brother´s are in too ...

    Sentiment: Strong Buy

  • ... to hedgies.
    The way you write shows - you are not convinced about what you write.
    It was the other way around before.

    Sentiment: Strong Buy

  • get648 get648 Nov 27, 2014 12:22 PM Flag

    AVNR closed at 14,47 in Frankfurt - 11,60 Euro is 14,47 $ today

    Sentiment: Strong Buy

  • ... all in what FDA requested!?

    goog for

    Sentiment: Strong Buy

  • Reply to

    FDA requested data for AVP-825 ...

    by get648 Nov 19, 2014 12:42 PM
    get648 get648 Nov 19, 2014 12:55 PM Flag

    results ...

    Two hundred and thirty patients (116 AVP-825 and 114 placebo device) were randomized, of whom 223 (112 and 111, respectively) experienced a qualifying migraine headache (their next migraine headache that reached moderate or severe intensity). A significantly greater proportion of AVP-825 patients reported headache relief at 2 hours post-dose compared with those using the placebo device (68% vs 45%, P = .002, odds ratio 2.53, 95% confidence interval [1.45, 4.42]). Between-group differences in headache relief were evident as early as 15 minutes, reached statistical significance at 30 minutes post-dose (42% vs 27%, P = .03), and were sustained at 24 hours (44% vs 24%, P = .002) and 48 hours (34% vs 20%, P = .01). Thirty-four percent of patients treated with AVP-825 were pain-free at 2 hours compared with 17% using the placebo device (P = .008). More AVP-825 patients reported meaningful pain relief (patient interpretation) of migraine within 2 hours of treatment vs placebo device (70% vs 45%, P 

    Sentiment: Strong Buy

  • ... AVNR could use results from OPTINOSE trial - results published october 31 2014

    Sentiment: Strong Buy

  • Reply to

    future of avanir is great ...

    by get648 Nov 8, 2014 4:32 PM
    get648 get648 Nov 8, 2014 4:38 PM Flag

    Avanir is the top-performing stock in the 118-member Nasdaq Biotechnology Index this year. Analysts predict the price will climb an additional 44 percent in the next 12 months should it remain a stand-alone entity, according to the average of six estimates compiled by Bloomberg. All of those analysts recommend investors purchase shares.

    The company is open to doing deals and is always looking for potential assets or companies to acquire, or even a good partner, Chief Business Officer Gregory Flesher said in a phone interview.

    “If there’s another company that we could come together with that would really make sense, we’d be open to that,” Flesher said.

    Ian Clements, a spokesman for Aliso Viejo, California-based Avanir, declined to comment on whether it’s hired advisers or what options it may be exploring, including a sale.
    Treating Outbursts

    Representatives for Dublin-based Shire and St. Louis-based Mallinckrodt declined to comment on whether they’re considering buying Avanir. Representatives for Copenhagen-based Lundbeck and Indianapolis-based Eli Lilly didn’t respond to phone calls or e-mails seeking comment.

    Avanir’s Nuedexta, which makes up almost all of the company’s sales, is approved to treat pseudobulbar affect (PBA), or uncontrollable crying or laughing believed to be caused by neurologic conditions such as Alzheimer’s, Parkinson’s and multiple sclerosis. Analysts estimate the drug generated $113 million of revenue in the fiscal year that ended Sept. 30. The April court ruling gave Nuedexta exclusivity through 2026.
    Alzheimer’s Potential

    A version of the medicine “significantly” reduced agitation in Alzheimer’s patients in the phase 2 study, Avanir said. The next steps for Avanir are to finalize the phase 3 trial design with the U.S. Food and Drug Administration, conduct it and then potentially secure approval in a couple of years.

    “Because the phase 2 data was so positive, people have a lot of confidence that phase 3 will be successful,” JMP’s Butler

    Sentiment: Strong Buy

  • Avanir Inroads in Alzheimer’s Justify Offers: Real M&A
    By Tara Lachapelle and David Welch Oct 30, 2014 9:19 PM GMT+0100

    Avanir Pharmaceuticals Inc. (AVNR) is giving suitors two reasons to bid.

    The $2.35 billion maker of a drug that controls abnormal emotional outbursts won a patent case in April that will stave off generic competition for 12 years. Then, phase 2 study data last month put the medicine on the road to approval for treating another condition with far greater revenue potential: agitation in Alzheimer’s patients. All the good news has more than tripled Avanir’s stock price this year and may get buyers’ attention.

    Eli Lilly & Co. (LLY), H. Lundbeck A/S, Mallinckrodt Plc (MNK) and Shire Plc (SHP) would be logical acquirers, according to JMP Group Inc. Those drugmakers either have an Alzheimer’s-related medicine or other treatments for conditions affecting the body’s central nervous system. Shire’s chief executive officer said that he will continue seeking deal opportunities after AbbVie Inc. dropped plans to buy the company last week.

    “There’s been two important events this year that could arguably make Avanir much more attractive from an acquisition perspective,” Jason Butler, a New York-based analyst at JMP, said in a phone interview. “Central nervous system assets that are approved and have this kind of growth potential are pretty scarce.”
    Recent Talks

    Avanir had been in talks last month about a merger or sale to another specialty drug company, according to a person with knowledge of the matter. When the company released the positive results of the phase 2 study Sept. 15, that spurred an 85 percent surge in the stock and put the deal out of range for Avanir’s potential partners, the person said. It also showed that the drug is a lower-risk investment, possibly making Avanir a target for larger drug companies, said the person, asking not to be named because the matter is private.

    Sentiment: Strong Buy

  • ... after the following studies are finished:

    A phase II study of sipuleucel-T (Provenge) with or without radiation therapy for patients with hormone-resistant metastatic prostate cancer (NCT01807065). This study is being conducted at the City of Hope Medical Center in Duarte, California; South Pasadena Cancer Center in Pasadena, California; and the Huntsman Cancer Institute, at the University of Utah (not yet open at this site).

    A phase II study of sipuleucel-T (Provenge) with enzalutamide (an androgen receptor inhibitor) in men with metastatic castration-resistant prostate cancer (NCT01981122).

    A phase II study of sipuleucel-T (Provenge) and indoximod, an IDO pathway inhibitor, for patients with refractory metastatic prostate cancer (NCT01560923). The IDO pathway is a biochemical pathway that is often more active in tumors; indoximod counteracts this effect. This trial is open at the University of Illinois Medical Center, Chicago, IL; the Masonic Cancer Center at the University of Minnesota, Minneapolis, MN; and the VA Medical Center at the University of Nebraska, Omaha, NE (not yet recruiting at this site).

    A phase II study of sipuleucel-T (Provenge) with or without pTVG-HP DNA booster vaccine in prostate cancer (NCT01706458). pTVG-HP is a DNA-based cancer vaccine containing DNA for prostatic acid phosphatase (PAP), the same cancer-associated antigen used in Provenge. This trial is being conducted at the University of Wisconsin Carbone Cancer Center, Madison, WI.

    Sentiment: Strong Buy

  • Reply to

    Can anyone explain what happened today?

    by legendinburgh Oct 27, 2014 6:38 PM
    get648 get648 Oct 27, 2014 6:56 PM Flag

    They want you to sell your shares!

    Sentiment: Strong Buy

  • goog for

    or read:
    30 Aug 2014

    I was prescribed NUEDEXTA "off label" for depression and it worked for me in 10 days.

    I had been on CYMBALTA & ABILIFY but they really weren't helping me as I continued to be seriously depressed (as a result of a traumatic brain injury and a stroke). The neurologist I saw is *highly acclaimed" within the medical community for his expertise and in the waiting room I spoke to a patient that just raved about him.

    The neurologist told me that he had prescribed NUEDEXTA to 200 patients that were depressed. (I don't know if their depression was a result of a neurological disability)

    Of those 200 patients, five (5) patients experienced side effects. Four (4) patients' side effects stopped between three (3) days and one (1) month. One patient did not experience any change in his level of depression.


    Sentiment: Strong Buy

  • goog for

    Sentiment: Strong Buy

  • from FDA - very soon!

    Sentiment: Strong Buy

  • shorts can´t go short any longer

    potential buyer is collecting all shares near 11,20

    NUEDEXTA will replace some SSRI´s, billion-market

    Sentiment: Strong Buy

  • very likely in 1 Q. 2015.
    Shorts know about and want to get in very cheap - and change their sentiment.

    Sentiment: Strong Buy

  • ...

    Dr. Daly is a blessing to the area of Psychology. I have been suffering for 22 years and no psychiatric prescription helped me. Dr. Daly suggested taking an MRI and a Cat Scan for my brain. The results showed that I had a disregulation in the frontal lobe of my brain. I was diagnosed with P.B.A. - Pseudobulbar Affect. I began treatment with Neurobiofeedback, in his office with Mike, a compassionate, kind, caring technician. I also began taking Nuedexta for my condition. It has been one year since I began treatment. I was doing Neurobiofeedback three times a week. Now I'm down to one time a week. I continue to take Nuedexta for P.B.A. I feel balanced, healthy and enthusiastic about life! Dr. Daly helped me to realize that Anti-depressants were not assisting me at all, for 22 years. His kind demeanor, jovial sense of humour and exceptional hospitatlity is refreshing, as I have been treated by hundreds of medical physicians in Windsor, London and Toronto.

    flag | Submitted Oct. 28, 2013


    Sentiment: Strong Buy

  • ... perfect prepared from KK.

    Sentiment: Strong Buy

  • Jan. 15, 6$ option calls.

    Sentiment: Strong Buy

  • Jan. 15, 6$ option calls

    Sentiment: Strong Buy

16.92+0.01(+0.06%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.